● Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Condition: Cervical Cancer · Sponsor: First Affiliated Hospital of Guangxi Medical University

PhasePhase 2

Planned participants112

Who can joinFemale, 18 Years to 70 Years

Healthy volunteersNo

About this study

To evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.

This description comes directly from the study's public registry record.

Talk to the study team

shanshan ma, M.D. · 07715356509 · 56716690@qq.com

yong zhang, M.D. · 07715356509 · zhangyonggx@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05511623